User login
Key clinical point: When choosing biologic medicines, patients with psoriatic arthritis (PsA) preferred oral medications and prioritized ability to work/lead a normal life and avoiding serious complications over clinical measures of improvement.
Major finding: Patients preferred oral vs. subcutaneous or intravenous routes (β coefficient 1.00; fixed parameter) and prioritized avoiding severe adverse events (β 0.72, 95% CI 0.50-0.95) and ability to attend normal activities (β 0.66; 95% CI 0.36-0.96) over improvement in enthesitis pain (β 0.28; 95% CI 0.20-0.36), psoriasis (β 0.28; 95% CI 0.20-0.36), and increasing chance of remission (β 0.27; 95% CI 0.19-0.36).
Study details: Findings are from a discrete choice experiment including 150 survey respondents with PsA, of which 75 patients were receiving biologics, 83 had an experience of biologic therapy, and 41 had an experience of 2 or more biologics.
Disclosures: The study had no funding to declare. Dr. Hassett declared receiving speaker fees or advisory board fees from AbbVie and Amgen.
Source: Sumpton D et al. Arthritis Care Res. 2021 Sep 13. doi: 10.1002/acr.24782.
Key clinical point: When choosing biologic medicines, patients with psoriatic arthritis (PsA) preferred oral medications and prioritized ability to work/lead a normal life and avoiding serious complications over clinical measures of improvement.
Major finding: Patients preferred oral vs. subcutaneous or intravenous routes (β coefficient 1.00; fixed parameter) and prioritized avoiding severe adverse events (β 0.72, 95% CI 0.50-0.95) and ability to attend normal activities (β 0.66; 95% CI 0.36-0.96) over improvement in enthesitis pain (β 0.28; 95% CI 0.20-0.36), psoriasis (β 0.28; 95% CI 0.20-0.36), and increasing chance of remission (β 0.27; 95% CI 0.19-0.36).
Study details: Findings are from a discrete choice experiment including 150 survey respondents with PsA, of which 75 patients were receiving biologics, 83 had an experience of biologic therapy, and 41 had an experience of 2 or more biologics.
Disclosures: The study had no funding to declare. Dr. Hassett declared receiving speaker fees or advisory board fees from AbbVie and Amgen.
Source: Sumpton D et al. Arthritis Care Res. 2021 Sep 13. doi: 10.1002/acr.24782.
Key clinical point: When choosing biologic medicines, patients with psoriatic arthritis (PsA) preferred oral medications and prioritized ability to work/lead a normal life and avoiding serious complications over clinical measures of improvement.
Major finding: Patients preferred oral vs. subcutaneous or intravenous routes (β coefficient 1.00; fixed parameter) and prioritized avoiding severe adverse events (β 0.72, 95% CI 0.50-0.95) and ability to attend normal activities (β 0.66; 95% CI 0.36-0.96) over improvement in enthesitis pain (β 0.28; 95% CI 0.20-0.36), psoriasis (β 0.28; 95% CI 0.20-0.36), and increasing chance of remission (β 0.27; 95% CI 0.19-0.36).
Study details: Findings are from a discrete choice experiment including 150 survey respondents with PsA, of which 75 patients were receiving biologics, 83 had an experience of biologic therapy, and 41 had an experience of 2 or more biologics.
Disclosures: The study had no funding to declare. Dr. Hassett declared receiving speaker fees or advisory board fees from AbbVie and Amgen.
Source: Sumpton D et al. Arthritis Care Res. 2021 Sep 13. doi: 10.1002/acr.24782.